These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 33940495)

  • 1. The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
    Sen S; Karabudak R; Schiavetti I; Demir S; Ozakbas S; Tutuncu M; Petek Balci B; Turan OF; Uzunkopru C; Koseoglu M; Yetkin MF; Gunduz T; Gumus H; Kale Icen N; Carmisciano L; Terzi M; Acar P; Gungor Dogan I; Baba C; Tuncer A; Uygunoglu U; Sormani MP; Efendi H; Siva A;
    Mult Scler Relat Disord; 2021 Jul; 52():102968. PubMed ID: 33940495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
    CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
    Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
    Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
    Kulikowska J; Czarnowska A; Gudowska-Sawczuk M; Kulczyńska-Przybik A; Bazylewicz M; Collins F; Chorąży M; Mroczko B; Kochanowicz J; Kapica-Topczewska K; Kułakowska A
    Neurol Neurochir Pol; 2023; 57(1):121-130. PubMed ID: 36421067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
    Louapre C; Collongues N; Stankoff B; Giannesini C; Papeix C; Bensa C; Deschamps R; Créange A; Wahab A; Pelletier J; Heinzlef O; Labauge P; Guilloton L; Ahle G; Goudot M; Bigaut K; Laplaud DA; Vukusic S; Lubetzki C; De Sèze J; ; Derouiche F; Tourbah A; Mathey G; Théaudin M; Sellal F; Dugay MH; Zéphir H; Vermersch P; Durand-Dubief F; Françoise R; Androdias-Condemine G; Pique J; Codjia P; Tilikete C; Marcaud V; Lebrun-Frenay C; Cohen M; Ungureanu A; Maillart E; Beigneux Y; Roux T; Corvol JC; Bordet A; Mathieu Y; Le Breton F; Boulos DD; Gout O; Guéguen A; Moulignier A; Boudot M; Chardain A; Coulette S; Manchon E; Ayache SS; Moreau T; Garcia PY; Kumaran D; Castelnovo G; Thouvenot E; Taithe F; Poupart J; Kwiatkowski A; Defer G; Derache N; Branger P; Biotti D; Ciron J; Clerc C; Vaillant M; Magy L; Montcuquet A; Kerschen P; Coustans M; Guennoc AM; Brochet B; Ouallet JC; Ruet A; Dulau C; Wiertlewski S; Berger E; Buch D; Bourre B; Pallix-Guiot M; Maurousset A; Audoin B; Rico A; Maarouf A; Edan G; Papassin J; Videt D
    JAMA Neurol; 2020 Sep; 77(9):1079-1088. PubMed ID: 32589189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study.
    Jameie M; Azizmohammad Looha M; Ebadi Z; Amanollahi M; Amani K; Nobahari F; Abdollahi A; Mousavi M; Pourghaz B; Harirchian MH
    BMC Neurol; 2024 Aug; 24(1):291. PubMed ID: 39164636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation.
    Mariottini A; Lotti A; Innocenti C; Repice AM; Nozzoli C; Boncompagni R; Fainardi E; Saccardi R; Massacesi L
    Eur J Neurol; 2023 Oct; 30(10):3362-3366. PubMed ID: 37483174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
    Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
    Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.
    Vercellino M; Bosa C; Alteno A; Muccio F; Marasciulo S; Garelli P; Cavalla P
    Mult Scler Relat Disord; 2023 Jun; 74():104715. PubMed ID: 37058763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
    Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
    Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
    J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.
    Smith TE; Madhavan M; Gratch D; Patel A; Saha V; Sammarco C; Rimler Z; Zuniga G; Gragui D; Charvet L; Cutter G; Krupp L; Kister I; Ryerson LZ
    Mult Scler Relat Disord; 2022 Apr; 60():103735. PubMed ID: 35398713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
    Etemadifar M; Abhari AP; Nouri H; Eighani N; Salari M; Sedaghat N
    J Neurol Sci; 2023 Jan; 444():120518. PubMed ID: 36521195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
    Sancho-Saldaña A; Gil-Sánchez A; González-Mingot C; Peralta S; Solana MJ; Torres P; Juanes A; Quibus L; Ruiz E; Sanpedro E; Quirant-Sánchez B; Martínez-Cáceres E; Ramo Tello C; Presas-Rodríguez S; García Rubio S; Baron BP; Ramió-Torrentà L; Sotoca J; González-Suárez I; Eichau S; Prieto-González JM; Blasco Quilez MR; Sabín-Muñoz J; Sánchez-López AJ; Llorens Calatayud G; Calles C; Sempere ÁP; Garcés M; Carmona O; Moral E; Hervás JV; Blanco Y; Sola-Valls N; Tellez Lara N; Forero L; Brieva L
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.
    Meltzer E; Charron O; Wozny J; Onuorah H; Montague A; Kline AC; Largent A; Krause TM; Freeman L
    Mult Scler Relat Disord; 2023 Dec; 80():105085. PubMed ID: 37931487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.